In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

Journal of Pathology

Volumn 224, Issue 3, 2011, Pages 389-400

  Ladoire, Sylvain ^a,b   Mignot, Grégoire ^b   Dabakuyo, Sandrine ^c   Arnould, Laurent ^d   Apetoh, Lionel ^b   Rébé, Cedric ^b   Coudert, Bruno ^a   Martin, Francois ^b   Bizollon, Marie Hélène ^e   Vanoli, André ^f   Coutant, Charles ^g   Fumoleau, Pierre ^a   Bonnetain, Franck ^c   Ghiringhelli, François ^a,b,h  

^a Georges Francois Leclerc Center   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Georges François Leclerc Center   (France)

^d Georges Francois Leclerc Cancer Centre   (France)

^e Sainte Marie Private Hospital ^*  (France)

^f Sainte Marie Private Hospital   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h Chu   (France)

Author keywords

breast; cancer; CD8; FOXP3; HER2; immune response; survival

Indexed keywords

CARBOPLATIN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, ADJUVANT; EPIDEMIOLOGIC METHODS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79958189573     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2866     Document Type: Article

References (42)

1. Kuerer HM, Newman LA, Smith TL, et al., Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469. (Pubitemid 29075229)
2. Romond EH, Perez EA, Bryant J, et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
4. Buzdar AU, Ibrahim NK, Francis D, et al., Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
5. Untch M, Rezai M, Loibl S, et al., Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28: 2024-2031.
6. Tamura K, Shimizu C, Hojo T, et al., FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2010; DOI: 10.1093/annonc/mdq585.
7. Spector NL, Blackwell KL,. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009; 27: 5838-5847.
8. Musolino A, Naldi N, Bortesi B, et al., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
9. Fontenot JD, Gavin MA, Rudensky AY,. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nature Immunol 2003; 4: 330-336. (Pubitemid 36432314)
10. Ormandy LA, Hillemann T, Wedemeyer H, et al., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-2464. (Pubitemid 40490158)
11. Woo EY, Chu CS, Goletz TJ, et al., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-4772. (Pubitemid 32691889)
12. Curiel TJ, Coukos G, Zou L, et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med 2004; 10: 942-9. (Pubitemid 39273735)
13. Ichihara F, Kono K, Takahashi A, et al., Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 4404-4408. (Pubitemid 37248397)
14. Bates GJ, Fox SB, Han C, et al., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380. (Pubitemid 46623168)
15. Mahmoud SM, Paish EC, Powe DG, et al., An evaluation of the clinical significance of FOXP3(+) infiltrating cells in human breast cancer. Breast Cancer Res Treat 2010; DOI: 10.1007/s10549-010-0987-8.
16. de Kruijf EM, van Nes JG, Sajet A, et al., The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010; 16: 1272-1280.
17. Perez SA, Karamouzis MV, Skarlos DV, et al., CD4 + CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 2007; 13: 2714-2721. (Pubitemid 46788040)
18. Ladoire S, Arnould L, Apetoh L, et al., Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14: 2413-2420. (Pubitemid 351551075)
19. Jeruss JS, Mittendorf EA, Tucker SL, et al., Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008; 26: 246-252.
20. Zitvogel L, Kroemer G,. The immune response against dying tumor cells: avoid disaster, achieve cure. Cell Death Differ 2008; 15: 1-2. (Pubitemid 350286166)
21. Apetoh L, Ghiringhelli F, Tesniere A, et al., The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59. (Pubitemid 350045573)
22. Pages F, Berger A, Camus M, et al., Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666. (Pubitemid 41817714)
23. Zhang L, Conejo-Garcia JR, Katsaros D, et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213. (Pubitemid 36077915)
24. DeNardo DG, Coussens LM,. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.
25. Aaltomaa S, Lipponen P, Eskelinen M, et al., Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992; 28A: 859-864.
26. Schmidt M, Bohm D, von Torne C, et al., The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68: 5405-5413.
27. Ladanyi A, Somlai B, Gilde K, et al., T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10: 521-530. (Pubitemid 38173990)
28. Vesalainen S, Lipponen P, Talja M, et al., Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30A: 1797-1803. (Pubitemid 24377155)
29. Nakano O, Sato M, Naito Y, et al., Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61: 5132-5136. (Pubitemid 32681545)
30. Schumacher K, Haensch W, Roefzaad C, et al., Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-3936. (Pubitemid 32720953)
31. Naito Y, Saito K, Shiiba K, et al., CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-3494. (Pubitemid 28376536)
32. Sato E, Olson SH, Ahn J, et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8 + /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-18543. (Pubitemid 43011261)
33. Kute TE, Savage L, Stehle JR Jr, et al., Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 2009; 58: 1887-1896.
34. Gennari R, Menard S, Fagnoni F, et al., Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5655. (Pubitemid 39180938)
35. Ghiringhelli F, Menard C, Terme M, et al., CD4 + CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202: 1075-1085. (Pubitemid 41464501)
36. Gobert M, Treilleux I, Bendriss-Vermare N, et al., Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69: 2000-2009.
37. Gao Q, Qiu SJ, Fan J, et al., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593. (Pubitemid 47041232)
38. Casares N, Pequignot MO, Tesniere A, et al., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701. (Pubitemid 41815875)
39. Obeid M, Tesniere A, Ghiringhelli F, et al., Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Med 2007; 13: 54-61. (Pubitemid 46067386)
40. Apetoh L, Ghiringhelli F, Tesniere A, et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Med 2007; 13: 1050-1059. (Pubitemid 47517504)
41. Ghiringhelli F, Apetoh L, Tesniere A, et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nature Med 2009; 15: 1170-1178.
42. Lake RA, Robinson BW,. Immunotherapy and chemotherapy-a practical partnership. Nature Rev Cancer 2005; 5: 397-405.